SCHEDULE 13G/A: BlackRock Boosts Stake in Tonix Pharma to 7.8%
Beneficial Ownership Report
BlackRock, Inc. has reported a 7.8% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. common stock as of September 30, 2025.
Summary
- BlackRock, Inc. beneficially owns 680,036 shares of Tonix Pharmaceuticals Holding Corp. common stock.
- This ownership represents 7.8% of the total outstanding common stock.
- BlackRock holds sole voting power over 665,586 shares and sole dispositive power over 680,036 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC, beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investor, BlackRock, has taken a substantial stake in Tonix Pharmaceuticals, which can be viewed positively by the market as a vote of confidence. However, it is purely a disclosure of ownership and does not provide operational or financial performance updates.
Positives
- Significant institutional investment from BlackRock, Inc. may signal confidence in Tonix Pharmaceuticals Holding Corp.'s prospects.
- BlackRock's substantial stake of 7.8% indicates a notable position in the company, potentially attracting further investor interest.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
The filing indicates continued institutional interest in the pharmaceutical and biotechnology sector, with major asset managers like BlackRock taking significant positions in companies such as Tonix Pharmaceuticals Holding Corp. This reflects broader investment trends where large funds allocate capital to specific industry segments, potentially signaling perceived growth opportunities or strategic value.
Stakeholder Impact
- Shareholders: Increased institutional ownership may lead to greater stability and potentially influence future stock performance. It could also signal a positive long-term outlook from a major investor.
- Management: The presence of a significant institutional investor like BlackRock may increase scrutiny on management decisions and corporate performance.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previous Power of Attorney, which was subsequently revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-09-30 | Date of the event requiring the filing of this statement, reflecting BlackRock's beneficial ownership. |
| 2025-10-17 | Date of filing and signature by BlackRock, Inc. |
Keywords
Tonix Pharmaceuticals, BlackRock, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.